Efficacy and safety of dulaglutide vs metformin in type 2 diabetes (AWARD-3)

被引：0
|
作者：
Tofe Povedano, S. [1 ]
Umpierrez, G. [2 ]
Perez Manghi, F. [3 ]
Shurzinske, L. [4 ]
Pechtner, V. [5 ]
机构：
[1] Clin Juaneda, Palma De Mallorca, Spain
[2] Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA USA
[3] Ctr Invest Metab CINME, Buenos Aires, DF, Argentina
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Neuilly Sur Seine, France
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [11] Efficacy and Safety of Dulaglutide versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1)
    Wysham, Carol
    Blevins, Thomas
    Arakaki, Richard
    Colon, Gildred
    Garcia, Pedro
    Atisso, Charles
    Kuhstoss, Debra
    Scism-Bacon, Jamie
    Lakshmanan, Mark
    DIABETES, 2013, 62 : A16 - A16
  • [12] Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
    Giorgino, Francesco
    Benroubi, Marian
    Sun, Jui-Hung
    Zimmermann, Alan G.
    Pechtner, Valeria
    DIABETES CARE, 2015, 38 (12) : 2241 - 2249
  • [13] Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1)
    Wysham, C.
    Blevins, T.
    Arakaki, R.
    Colon, G.
    Garcia, P.
    Atisso, C.
    Kuhstoss, D.
    Scism-Bacon, J.
    Lakshmanan, M.
    DIABETOLOGIA, 2013, 56 : S367 - S367
  • [14] EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM
    Davidson, Jaime A.
    Manghi, Federico Perez
    Yu, Maria
    Linetzky, Bruno
    Lando, Laura Fernandez
    ENDOCRINE PRACTICE, 2016, 22 (12) : 1406 - 1414
  • [15] Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
    Wysham, Carol
    Blevins, Thomas
    Arakaki, Richard
    Colon, Gildred
    Garcia, Pedro
    Atisso, Charles
    Kuhstoss, Debra
    Lakshmanan, Mark
    DIABETES CARE, 2014, 37 (08) : 2159 - 2167
  • [16] Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
    Jendle, Johan
    Grunberger, George
    Blevins, Thomas
    Giorgino, Francesco
    Hietpas, Ryan T.
    Botros, Fady T.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (08) : 776 - 790
  • [17] 1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)
    Michael A. Nauck
    Ruth S. Weinstock
    Guillermo E. Umpierrez
    Bruno Guerci
    Karen L. Boleyn
    Zachary Skrivanek
    Zvonko Milicevic
    Nederlands Tijdschrift voor Diabetologie, 2013, 11 (3) : 79 - 80
  • [18] Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials
    Reaney, M.
    Yu, M.
    Lakshmanan, M.
    Pechtner, V.
    van Brunt, K.
    DIABETES OBESITY & METABOLISM, 2015, 17 (09): : 896 - 903
  • [19] Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
    Frias, Juan P.
    Bonora, Enzo
    Nevarez Ruiz, Luis
    Li, Ying G.
    Yu, Zhuoxin
    Milicevic, Zvonko
    Malik, Raleigh
    Bethel, M. Angelyn
    Cox, David A.
    DIABETES CARE, 2021, 44 (03) : 765 - 773
  • [20] Efficacy and safety by duration of diabetes with once weekly dulaglutide in the AWARD programme
    Gallwitz, B.
    Thieu, V.
    Pavo, I.
    Jia, N.
    Zhang, N.
    Garcia-Perez, L. -E.
    DIABETOLOGIA, 2016, 59 : S75 - S75
12345